Our approved medicines

The medicines listed below have marketing authorizations in the jurisdictions listed, but may not be reimbursed or available through a specific country鈥檚 health care system. For more information, please contact听Medical Information.

Trademark
Generic Name
Therapy Area
Approved in the Following Countries

颁础厂骋贰痴驰鈩

exagamglogene autotemcel (exa-cel)

Sickle Cell Disease

Bahrain
England
European Union
Kingdom of Saudi Arabia
Scotland
United States
Wales

颁础厂骋贰痴驰鈩

exagamglogene autotemcel (exa-cel)

Transfusion-Dependent Beta Thalassemia

Bahrain
England
European Union
Kingdom of Saudi Arabia
Scotland
United States
Wales

TRIKAFTA

elexacaftor/tezacaftor/ivacaftor and ivacaftor

Cystic Fibrosis

Australia
Brazil
Canada
Chile
Israel
Liechtenstein
New Zealand
Russia
Switzerland
United States
Uruguay

KAFTRIO
in a combination regimen with ivacaftor

ivacaftor/tezacaftor/elexacaftor in combination with ivacaftor

Cystic Fibrosis

European Union
Iceland
Norway
United Kingdom

SYMDEKO

tezacaftor/ivacaftor and ivacaftor

Cystic Fibrosis

Australia
Brazil
Canada
Israel
Liechtenstein
New Zealand
Switzerland
United States

SYMKEVI
in a combination regimen with ivacaftor

tezacaftor/ivacaftor in combination with ivacaftor

Cystic Fibrosis

European Union
Iceland
Norway
United Kingdom

ORKAMBI

lumacaftor/ivacaftor

Cystic Fibrosis

Australia
Brazil
Canada
European Union
Iceland
Israel
Liechtenstein
New Zealand
Norway
Russia
Switzerland
United Kingdom
United States

KALYDECO

ivacaftor

Cystic Fibrosis

Australia
Brazil
Canada
European Union
Iceland
Israel
Liechtenstein
New Zealand
Norway
Oman
Switzerland
United Arab Emirates
United Kingdom
United States